Researcher
Annick Moens
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Aug 2017 → 11 Oct 2021
Projects
1 - 1 of 1
- LONG-TERM SEQUENTIAL USE OF BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE: HARMLESS OR HAZARDOUS?From1 Aug 2017 → 24 Sep 2021Funding: FWO fellowships
Publications
1 - 10 of 11
- Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study](2022)
Authors: Annick Moens
Pages: 1428 - 1435 - Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral centre(2022)
Authors: Annick Moens, Nasim Sadat Seyed Tabib, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 271 - 281 - LONG-TERM SAFETY OF THE (SEQUENTIAL) USE OF BIOLOGICAL THERAPIES IN INFLAMMATORY BOWEL DISEASES(2021)
Authors: Annick Moens, Marc Ferrante, Séverine Vermeire
- Update on the Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding(2020)
Authors: Annick Moens, Marc Ferrante
Pages: 27 - 42 - Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center(2020)
Authors: Annick Moens, Matthias Lenfant, Gert Van Assche, Séverine Vermeire, Ann Gils, Marc Ferrante
Pages: 628 - 634 - Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study(2020)
Authors: Annick Moens, C Janneke van der Woude, Mette Julsgaard, Evelien Humblet, Juliette Sheridan, Daniel C Baumgart, Cyrielle Gilletta De Saint-Joseph, Stephane Nancey, Jean-Francois Rahier, Peter Bossuyt, et al.
Pages: 129 - 138 - Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study(2019)
Authors: Annick Moens, Peter Bossuyt, Séverine Vermeire, Marc Ferrante
Pages: 129 - 138 - Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decades(2019)
Authors: Annick Moens, Bram Verstockt, Kathleen Machiels, Peter Bossuyt, Katrien Lagrou, Gert Van Assche, Séverine Vermeire, Marc Ferrante
Pages: 668 - 673 - Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab(2019)
Authors: Annick Moens, Karen van Hoeve, Peter Bossuyt, Séverine Vermeire, Marc Ferrante
Pages: 12 - 18 - Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy(2017)
Authors: Marc Ferrante, Anthony de Buck van Overstraeten, Annick Moens, Gert Van Assche, Albert Wolthuis, Séverine Vermeire
Pages: 1353 - 1361